COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,703 Articles (22,913 medRxiv, 8,790 bioRxiv)

Most recent first Previous |  Page 869: Articles 8681-8690  | Next

Analysis of severe illness after post-vaccination COVID-19 breakthrough among adults with and without HIV in the United States
Lang, R., Humes, E., Coburn, S. B., Horberg, M. A., Fathi, L. F., Watson, E., Jefferson, C. R., Park, L. S., Justice, A. C., Gordon, K. S., Akgun, K. M., Napravnik, S., Edwards, J. K., Browne, L. E., Agil, D. M., Silverberg, M. J., Skarbinski, J., Leyden, W. A., Stewart, C., Hogan, B. C., Gebo, K. A., Marconi, V. C., Williams, C. F., Althoff, K. N., for the Corona-Infectious-Virus Epidemiology Team (CIVETs) of the NA-ACCORD of IeDEA
10.1101/2022.04.15.22273913 — Posted: 2022-04-16
COVID-19 relevant genetic variants confirmed in an admixed population
Texis, T., Cruz-Jaramilllo, J. L., Garcia-Munoz, W., Anzures-Cortes, L., Hadadd-Talancon, L., Sanchez-Garcia, S., Jimenez-Martinez, M. d. C., Perez-Barragan, E., Nieto-Patlan, A., Martinez-Ezquerro, J. D., Rubio-Carrasco, K., Rodriguez-Dorantes, M., Cortes-Ramirez, S., Mellado-Sanchez, G., Perez-Tapia, S. M., Gonzalez-Covarrubias, V.
10.1101/2022.04.15.22273925 — Posted: 2022-04-16
Profile of Brazilian inpatients with COVID-19 vaccine breakthrough infection and risk factors for unfavorable outcome
de Jesus, M. A. S., Hojo-Souza, N. S., de Moraes, T. R., Guidoni, D. L., Souza, F. S. H.
10.1101/2022.04.12.22273589 — Posted: 2022-04-16
Dose-response modelling of endemic coronavirus and SARS-CoV-2: human challenge trials reveal the individual variation in susceptibility
Miura, F., Klinkenberg, D., Wallinga, J.
10.1101/2022.04.07.22273549 — Posted: 2022-04-16
Effectiveness of COVID-19 mRNA vaccine booster dose relative to primary series during a period of Omicron circulation
Petrie, J. G., King, J. P., McClure, D. L., Rolfes, M. A., Meece, J. K., Belongia, E. A., McLean, H. Q.
10.1101/2022.04.15.22273915 — Posted: 2022-04-16
A meta-epidemiological assessment of transparency indicators of infectious disease models
Zavalis, E. A., Ioannidis, J.
10.1101/2022.04.11.22273744 — Posted: 2022-04-16
Monitoring real-time transmission heterogeneity from Incidence data
Zhang, Y., Britton, T., Zhou, X.
10.1101/2022.04.07.22273591 — Posted: 2022-04-16
Heterologous Gam-COVID-Vac (Sputnik V) / mRNA-1273 (Moderna) vaccination induces a stronger humoral response than homologous Sputnik V in a real-world data analysis
Pereson, M. J., Amaya, L., Neukam, K., Bare, P., Echegoyen, N., Badano, M. N., Lucero, A., Martelli, A., Garcia, G., Videla, C., Martinez, A., Di Lello, F. A.
10.1101/2022.04.08.22273532 — Posted: 2022-04-16
SARS-CoV-2 spike 340 and 337 mutations in Omicron variants are selected after Sotrovimab infusion in immunocompromised patients
destras, g., bal, a., simon, b., lina, b., josset, l.
10.1101/2022.04.08.22273513 — Posted: 2022-04-16
Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study
Zheng, H., Cao, Y., Chen, X., Wang, F., Hu, Y., Song, W., Chai, Y., Gu, Q., Shi, Y., Feng, Y., Liu, S., Xie, Y., Xie, X. S., Jiang, W., Shen, Z.
10.1101/2022.04.09.22273653 — Posted: 2022-04-16

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).